Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
How Is the Multiplex Biomarker Imaging Market Size Expected to Evolve From 2025 to 2029?
The multiplex biomarker imaging market size has grown rapidly in recent years. It will grow from $0.49 billion in 2024 to $0.54 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to the high incidence of cancer, the need for precise diagnostic tools, the growing prevalence of chronic diseases, the increase in the aging population, and the shift towards personalized medicine.
The multiplex biomarker imaging market size is expected to see rapid growth in the next few years. It will grow to " $0.8 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing emphasis on personalized medicine, increased research and development activities, increasing clinical trials, the need for high throughput screening methods in drug discovery, and supportive regulatory frameworks and guidelines. Major trends in the forecast period include technological advancements, innovations in imaging technologies, advances in digital pathology, developments in data analysis and imaging software, and integration of AI and machine learning with imaging technologies.
Get your free report sample today:
What Are the Leading Drivers Behind the Growth of the Multiplex Biomarker Imaging Market?
The rising prevalence of chronic diseases is expected to propel the growth of the multiplex biomarker imaging market going forward. Chronic diseases are long-lasting health conditions that persist or recur over time, often with complex causes, multiple risk factors, and long latency periods. The growing prevalence of chronic diseases is attributed to several factors, including the rapid aging of the population, improved case finding and detection, better treatment and management of diseases, and changes in lifestyle and environmental risk factors. Multiplex biomarker imaging is utilized in chronic disease management for comprehensive analysis and characterization of disease progression and treatment response. For instance, in January 2023, according to a report published by the National Institutes of Health (NIH), a US-based biomedical research agency, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.52 million in 2020 to 142.66 million in 2050. Therefore, the rising prevalence of chronic diseases is driving the growth of the multiplex biomarker imaging market.
What Are the Emerging Segments Driving Growth in the Multiplex Biomarker Imaging Market?
The multiplex biomarker imagingmarket covered in this report is segmented –
1) By Component Type: Instruments; Software; Services
2) By Imaging Techniques: Immuno Fluorescence (IF) Assay; Tissue Microarray (TMA) Assay; Immunohistochemistry (IHC) Assay; Fluorescent In The Situ Hybridization (FISH) Assay; Toponome Imaging System (TIS)
3) By Application: Drug Safety; Oncology Studies; Genetic Characterization Studies
4) By End User: Research Institutes Government And Private; Clinical Labs; Pharmaceutical And Biotechnology
Subsegments:
1) By Instruments: Imaging Systems (Microscopes, Scanners); Detection Devices (Sensors, Probes); Reagents And Kits
2) By Software: Image Analysis Software; Data Management Software; Visualization And Interpretation Software
3) By Services: Technical Support And Maintenance; Consultation And Training; Imaging And Analysis Services
What Are the Key Industry Trends Driving Growth in the Multiplex Biomarker Imaging Market?
Major companies operating in the multiplex biomarker imaging market are focusing on providing innovative slides, such as automated slide loaders, to provide advanced imaging solutions and better serve customers. Automated slide loaders streamline sample handling, reducing hands-on time and enhancing throughput, which is crucial for high-volume multiplex biomarker imaging experiments. For instance, in April 2024, Standard BioTools Inc., a US-based provider of analytical systems and instruments, launched a Hyperion XTi Imaging System with a new high-throughput multiplexed whole slide to add automation and flexibility. It has three modes for rapid analysis, including preview, tissue, and cell modes. Researchers can visualize tissue heterogeneity quickly and conduct deeper analysis. This novel whole slide imaging method using imaging mass cytometry (IMC) offers up to 10 times higher throughput than cyclic immunofluorescent imaging. Additionally, a new automated slide loader facilitates high-throughput imaging, reducing hands-on time and enabling standardization. These innovations aimed to accelerate breakthroughs in spatial proteomics, providing reliable insights into health and disease.
Who Are the Principal Market Leaders in the Multiplex Biomarker Imaging Market?
Major companies operating in the multiplex biomarker imaging market are Merck KGaA, Thermo Fisher Scientific Inc., Danaher corporation, Becton Dickinson and Company (BD), Carl Zeiss AG, Illumina Inc, PerkinElmer Inc., Bio-Rad Laboratories Inc, Bruker Corporation, Bio-Techne Corporation, Leica Biosystems Nussloch GmbH, Abcam Plc, Meso Scale Diagnostics LLC, Fluidigm Corporation, NanoString Technologies, Quanterix Corporation, Akoya Biosciences, Enzo Biochem Inc, Cisbio Bioassays, Flagship Biosciences, Aushon BioSystems Ltd, Ionpath Inc., Biosims Technologies
Get the detailed multiplex biomarker imaging market report today
Which Regions Are Expected to Record the Strongest CAGR in the Multiplex Biomarker Imaging Market?
North America was the largest region in the multiplex biomarker imaging market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiplex biomarker imaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment